Design and Synthesis of a Potent and Selective Triazolone-Based Peroxisome Proliferator-Activated Receptor α Agonist

Journal of Medicinal Chemistry

Volumn 46, Issue 24, 2003, Pages 5121-5124

  Xu, Yanping ^a   Mayhugh, Daniel ^a   Saeed, Ashraf ^a   Wang, Xiaodong ^a   Thompson, Richard C ^a   Dominianni, Samuel J ^a   Kauffman, Raymond F ^a   Singh, Jaipal ^a   Bean, James S ^a   Bensch, William R ^a   Barr, Robert J ^a   Osborne, John ^a   Montrose Rafizadeh, Chahrzad ^a   Zink, Richard W ^a   Yumibe, Nathan P ^a   Huang, Naijia ^a   Luffer Atlas, Debra ^a   Rungta, Deepa ^b   Maise, Dale E ^b   Mantlo, Nathan B ^a  

^a ELI LILLY AND COMPANY   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 [3 (2,4 DIFLUOROPHENYL) 1 HEPTYLUREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 2,4 DIHYDRO 3H 1,2,4 TRIAZOL 3 ONE; APOLIPOPROTEIN A1; FENOFIBRATE; FENOFIBRIC ACID; GW 7647; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LY 518674; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; ISCHEMIC HEART DISEASE; MOUSE; NONHUMAN; REACTION ANALYSIS; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; ANIMALS; APOLIPOPROTEIN A-I; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; CELL LINE; DOGS; DRUG DESIGN; HUMANS; MICE; MICE, TRANSGENIC; PROPIONATES; RADIOLIGAND ASSAY; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS; TRANSFECTION; TRIAZOLES;

EID: 0242522918     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm034173l     Document Type: Article

References (22)

1. Lemberger, T.; Desvergne, B.; Wahli, W. Peroxisome Proliferator-Activated Receptors: A Nuclear Receptor Signaling Pathway in Lipid Physiology. Annu. Rev. Cell Dev. Biol. 1996, 12, 335-363.
2. Willson, T.; Brown, P.; Sternbach, D.; Henke, B. The PPARs: From Orphan Receptors to Drug Discovery. J. Med. Chem. 2000, 43, 527-550.
3. Kliewer, S. A.; Umesono, K.; Noonan, D. J.; Heyman, R. A.; Evans, R. M. Convergence of 9-cis Retinoic Acid and Peroxisome Proliferator Signaling Pathways Through Heterodimer Fomation of Their Receptors. Nature 1992, 358, 771-774.
4. Freedman, L. P. Increasing the Complexity of Coactivation in Nuclear Receptor Signaling. Cell 1999, 97, 508.
5. Torra, I. P.; Chinetti, G.; Duval, C.; Fruchart, J. C. Staels, B. Peroxisome Proliferator-Activated Receptors: From Transcriptional Control to Clinical Practice. Curr. Opin. Lipidol. 2001, 12, 245-254.
6. Tugwood, J. D.; Issemann, I.; Anderson, R. G.; Bundell, K. R.; McPheat, W. L.; Green, S. The Mouse Peroxisome Proliferator Activated Receptor Recognizes a Response Element in the 5′ Flanking Sequence of the Rat Acyl CoA Oxidase Gene. EMBO J. 1992, 11, 433-439.
7. Issemann, I.; Prince, R.; Tugwood, J.; Green, S. A Role for Fatty Acids and Liver Fatty Acid Binding Protein in Peroxisome Proliferation? Biochem. Soc. Trans. 1992, 20, 824-827.
8. Hertz, R.; Bishara-Shieban, J.; Bar-Tana, J. Mode of Action of Peroxisome Proliferators as Hypolidemic Drugs, Suppression of Apolipoprotein C-III. J. Biol. Chem. 1995, 270, 13470-13475.
9. Schoonjans, K.; Peinado-Onsurbe, J.; Lefebvre, A. M.; Heyman, R. A.; Briggs, M.; Deeb, S.; Staels, B.; Auwerx, J. PPARα Activators Direct a Distinct Tissue-Specific Transcriptional Response Via a PPRE in the Lipoprotein Lipase Gene. EMBO J. 1996, 15, 5336-5348.
10. Chong, P. H.; Bachenheimer, B. S. Current, New and Future Treatments in Dyslipidaemia and Atherosclerosis. Drugs 2000, 60, 55-93.
11. Milionis, H. J.; Elisaf, M. S.; Mikhailidis, D. P. Treatment of Dyslipidaemias in Patients with Established Vascular Disease: A Revival of the Fibrates. Curr. Med. Res. Opin. 2000, 16, 21-32.
12. Staels, B.; Auwerx, J. Role of PPAR in the Pharmacological Regulation of Lipoprotein Metabolism by Fibrates and Thiazolidinediones. Curr. Pharm. Des. 1997, 3, 1-14.
13. Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J. C. Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation 1998, 98, 2088-2093.
14. (a) Brown, P. J.; Winegar, D. A.; Plunket, K. D.; Moore, L. B.; Lewis, M. C.; Wilson, J. G.; Sundseth, S. S.; Koble, C. S.; Wu, Z.; Chapman, J. M.; Lehmann, J. M.; Kliewer, S. A.; Willson, T. M. A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPARα Agonist with Potent Lipid-Lowering Activity. J. Med. Chem. 1999, 42, 3785-3788.
15. (b) Brown, P. J.; Stuart, L. W.; Hurley, K. P.; Lewis, M. C.; Winegar, D. A.; Wilson, J. G.; Wilkison, W. O.; Ittoop, O. R.; Willson, T. M.; Identification of a Subtype Selective Human PPARα Agonist Through Parallel-Array Synthesis. Bioorg. Med. Chem. Lett. 2001, 11, 1225-1227.
16. Miyachi, H.; Nomura, M.; Tanase, T.; Suzuki, M.; Murakami, K.; Awano, K. Enantio-Dependent Binding and Transactivation of Optically Active Phenylpropanoic Acid Derivatives at Human Peroxisome Proliferator-Activated Receptor Alpha. Bio. Med. Chem. 2002, 12, 333-335.
17. Kubota, S.; Uda, M. 1,2,4-Triazoles. III. The Tautomerism of 3-Phenyl-1,2,4-Triazolin-5-One, 3-Phenyl-1,2,4-Triazolme-5-Thione and Their N-Methyl Derivatives. Chem. Pharm. Bull. 1973, 21, 1342-1350.
18. Kane, J. M.; Baron, B. M.; Dudley, M. W.; Sorensen, S. M.; Staeger, M. A.; Miller, F. P. 2,4 Dihydro-3H-1,2,4-Triazol-3-Ones as Anticonvulsant Agents. J. Med. Chem. 1990, 33, 2772-2777.
19. Madding, G. D.; Smith, D. W.; Sheldon, R. I.; Lee, B. Synthesis and X-ray Crystal Structure of a 2,4,5-Trisubstituted 1,2,4-Triazolin-3-One. J. Heterocycl. Chem. 1985, 22, 1121-1126.
20. Chang, L. L.; Ashton, W. T.; Flanagan, K. L.; Strelitz, R. A.; MacCoss, M.; Greenlee, W. J.; Chang, R. S. L.; Lotti, V. J.; Faust, K. A.; Chen, T. B.; Bunting, P.; Zingaro, G. J.; Kivlighn, S. D.; Siegl, P. K. S. Triazolinones as Nonpeptide Angiotensin II Antagonists. I. Synthesis and Evaluation of Potent 2,4,5-Trisubstituted Triazolinones. J. Med. Chem. 1993, 36, 2558-2568.
21. Berthou, L.; Duverger, N.; Emmanuel, F.; Langouet, S.; Auwerx, J.; Guillouzo, A.; Fruchart, J. C.; Rubin, E.; Denefle, P.; Staels, B.; Branellex, D. Opposite Regulation of Human Versus Mouse Apolipoprotein A-I by Fibrates in Human Apolipoprotein A-I Transgenic Mice. J. Clin. Invest. 1996, 97, 2408-2416.
22. Johnson, T. E.; Holloway, M. K.; Vogel, R.; Rutledge, S. J.; Perkins, J. J.; Rodan, G. A.; Schmidt, A. Structural Requirements and Cell-Type Specificity for Ligand Activation of Peroxisome Proliferator-Activated Receptors. J. Steroid Biochem. Mol. Biol. 1997, 63, 1-8.